Intratumoral distribution and pharmacokinetics of the radiolabeled ICAM-1 targeting monoclonal antibody R6.5 in a prostate cancer mouse model
Anders Örbom, Susan Evans-Axelsson, Bo Jansson, Oskar Vilhelmsson Timmermand, Thuy A. Tran, Anders Bjartell, Sven-Erik Strand · Nuklearmedizin - NuclearMedicine · 2025 · Heft 02 · S. 163-169
Bibliografische Angaben
Zusammenfassung
Abstract Aim Despite new therapies, castration-resistant prostate cancer (CRPC) is still incurable. Intercellular Adhesion Molecule 1 (ICAM-1) is a well-characterized cell surface protein involved in prostate cancer pathogenesis, differentially expressed during transition from hormone-sensitive to CRPC. This study aimed to investigate ICAM-1 as a target for imaging and radioimmunotherapy of CRPC. Methods Anti-ICAM-1 antibody R6.5 was labeled with 111In or 177Lu, and a non-specific antibody with 177Lu. In vitro uptake of R6.5 was tested in PC-3 prostate cancer cells. Biodistribution studies, SPECT/CT imaging, and…
